Page last updated: 2024-12-07

6-deoxyerythronolide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-deoxyerythronolide B is a macrolide antibiotic that is produced by the bacterium Saccharopolyspora erythraea. It is an important intermediate in the biosynthesis of erythromycin, and its synthesis has been extensively studied. The compound is of particular interest to researchers because it exhibits antibacterial activity against a wide range of Gram-positive bacteria. Research on 6-deoxyerythronolide B has led to a better understanding of the biosynthesis of erythromycin, and has also provided insights into the design and development of new antibiotics.'

6-deoxyerythronolide B: Streptomyces erythreus metabolite; presumed intermediate in biosynthesis of erythromycins; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121904
CHEBI ID16089
SCHEMBL ID12266551
MeSH IDM0105738

Synonyms (18)

Synonym
6,12-dideoxy-erythronolide a
CHEBI:16089
3,5,11-trihydroxyerythranolid-9-one
(3r,4s,5r,6s,7s,9r,11r,12s,13r,14r)-14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
15797-36-1
C03240
6-deoxyerythronolide b
DB04070
LMPK04000002
(3r,4s,5r,6s,7s,9r,11r,12s,13r,14r)-14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
erythronolide a, 6,12-dideoxy-
SCHEMBL12266551
HQZOLNNEQAKEHT-IBBGRPSASA-N
6-desoxyerythronolid b
14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
DTXSID50935833
Q27094923
PD006504

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" More specifically, the heterologous proteins responsible for 6dEB production were varied by adjusting their respective gene dosage levels."( Probing the heterologous metabolism supporting 6-deoxyerythronolide B biosynthesis in Escherichia coli.
Boghigian, B; Pfeifer, BA; Wang, Y; Zhang, H, 2009
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
erythronolide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
superpathway of erythromycin biosynthesis1842
superpathway of megalomicin A biosynthesis842
erythromycin D biosynthesis618
superpathway of erythromycin biosynthesis (without sugar biosynthesis)823

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.90)18.7374
1990's16 (23.19)18.2507
2000's33 (47.83)29.6817
2010's17 (24.64)24.3611
2020's1 (1.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.71 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (4.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (95.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]